Watson Settles Androderm False Marking Suit

Law360, New York (February 2, 2011, 4:25 PM EST) -- Watson Pharmaceuticals Inc. has agreed to stop using packaging for its Androderm testosterone deficiency treatment allegedly labeled with expired patents in order to settle a false marking suit accusing the company of blocking innovation in the industry.

Judge T. John Ward of the U.S. District Court for the Eastern District of Texas signed off on a stipulated dismissal between Watson and qui tam plaintiff Promote Innovation LLC on Tuesday.

The order calls for Watson and any companies selling its Androderm products to stop using the labels,...
To view the full article, register now.